 Megan Curran
Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rheumatology | 5 | 2024 | 87 | 2.330 |
Why?
| | Education, Medical, Graduate | 7 | 2024 | 366 | 2.240 |
Why?
| | Clinical Competence | 8 | 2024 | 882 | 1.500 |
Why?
| | Fellowships and Scholarships | 6 | 2024 | 224 | 1.210 |
Why?
| | Dermatomyositis | 6 | 2020 | 23 | 1.150 |
Why?
| | Sjogren's Syndrome | 2 | 2021 | 40 | 0.910 |
Why?
| | Pediatrics | 5 | 2024 | 981 | 0.850 |
Why?
| | Lupus Erythematosus, Systemic | 5 | 2022 | 221 | 0.840 |
Why?
| | Education, Distance | 1 | 2020 | 38 | 0.650 |
Why?
| | Hemorrhage | 1 | 2021 | 599 | 0.560 |
Why?
| | Educational Measurement | 1 | 2019 | 225 | 0.550 |
Why?
| | Arthritis, Juvenile | 2 | 2020 | 42 | 0.550 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2015 | 7 | 0.510 |
Why?
| | Arthralgia | 2 | 2014 | 46 | 0.480 |
Why?
| | Lung Diseases | 1 | 2021 | 688 | 0.480 |
Why?
| | Program Evaluation | 1 | 2019 | 821 | 0.470 |
Why?
| | Mental Health | 2 | 2020 | 559 | 0.460 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 60 | 0.410 |
Why?
| | Shoes | 1 | 2012 | 21 | 0.400 |
Why?
| | Arthritis | 1 | 2013 | 109 | 0.390 |
Why?
| | Antibodies, Antinuclear | 1 | 2012 | 59 | 0.390 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2020 | 1168 | 0.380 |
Why?
| | Face | 1 | 2013 | 163 | 0.380 |
Why?
| | Scleroderma, Systemic | 2 | 2023 | 90 | 0.350 |
Why?
| | Leg | 1 | 2012 | 218 | 0.350 |
Why?
| | Mycobacterium tuberculosis | 1 | 2013 | 268 | 0.340 |
Why?
| | Joint Instability | 1 | 2012 | 162 | 0.330 |
Why?
| | Competency-Based Education | 4 | 2023 | 62 | 0.330 |
Why?
| | Internship and Residency | 3 | 2023 | 920 | 0.320 |
Why?
| | Lupus Erythematosus, Discoid | 2 | 2022 | 6 | 0.320 |
Why?
| | Anxiety | 1 | 2015 | 837 | 0.320 |
Why?
| | Knee Joint | 1 | 2012 | 321 | 0.320 |
Why?
| | Child | 20 | 2023 | 18340 | 0.300 |
Why?
| | Depression | 1 | 2015 | 1131 | 0.280 |
Why?
| | Risk Assessment | 1 | 2015 | 2953 | 0.270 |
Why?
| | Humans | 33 | 2024 | 113531 | 0.250 |
Why?
| | Diagnosis, Differential | 4 | 2014 | 1328 | 0.240 |
Why?
| | Age of Onset | 3 | 2021 | 444 | 0.230 |
Why?
| | Raynaud Disease | 1 | 2023 | 5 | 0.220 |
Why?
| | Psoriasis | 1 | 2023 | 80 | 0.200 |
Why?
| | Edema | 2 | 2013 | 119 | 0.190 |
Why?
| | Specialization | 1 | 2021 | 112 | 0.180 |
Why?
| | Trust | 1 | 2021 | 103 | 0.180 |
Why?
| | Purpura, Hyperglobulinemic | 1 | 2020 | 1 | 0.170 |
Why?
| | Videoconferencing | 1 | 2020 | 57 | 0.170 |
Why?
| | Purpura | 1 | 2020 | 12 | 0.170 |
Why?
| | Adalimumab | 1 | 2020 | 44 | 0.170 |
Why?
| | Ocular Motility Disorders | 1 | 2020 | 25 | 0.170 |
Why?
| | Dermatitis, Atopic | 1 | 2023 | 304 | 0.170 |
Why?
| | Female | 14 | 2022 | 59115 | 0.170 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2015 | 3252 | 0.170 |
Why?
| | Extracellular Traps | 1 | 2020 | 39 | 0.160 |
Why?
| | Agammaglobulinemia | 1 | 2019 | 30 | 0.160 |
Why?
| | Physical Examination | 1 | 2020 | 222 | 0.160 |
Why?
| | Patient Simulation | 1 | 2019 | 29 | 0.160 |
Why?
| | Consensus | 4 | 2023 | 533 | 0.160 |
Why?
| | Rituximab | 1 | 2019 | 146 | 0.150 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 379 | 0.150 |
Why?
| | Child Behavior | 1 | 2020 | 217 | 0.150 |
Why?
| | Vascular Diseases | 1 | 2021 | 231 | 0.150 |
Why?
| | Professional Competence | 1 | 2018 | 84 | 0.140 |
Why?
| | Antirheumatic Agents | 1 | 2019 | 253 | 0.140 |
Why?
| | Disability Evaluation | 1 | 2018 | 271 | 0.140 |
Why?
| | Steroids | 2 | 2020 | 138 | 0.130 |
Why?
| | Adolescent | 11 | 2022 | 17724 | 0.130 |
Why?
| | Patient Care Planning | 1 | 2017 | 138 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2021 | 494 | 0.130 |
Why?
| | Adolescent Behavior | 1 | 2020 | 481 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 333 | 0.120 |
Why?
| | Internet | 1 | 2020 | 590 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 325 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2021 | 1008 | 0.120 |
Why?
| | Neutrophils | 1 | 2020 | 1072 | 0.120 |
Why?
| | Reproducibility of Results | 2 | 2019 | 2752 | 0.120 |
Why?
| | United States | 4 | 2021 | 12137 | 0.110 |
Why?
| | Laryngeal Diseases | 1 | 2013 | 21 | 0.110 |
Why?
| | Stress, Psychological | 1 | 2020 | 940 | 0.100 |
Why?
| | Parents | 1 | 2020 | 1175 | 0.100 |
Why?
| | Hypothyroidism | 1 | 2013 | 65 | 0.100 |
Why?
| | Myocarditis | 1 | 2014 | 92 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1308 | 0.100 |
Why?
| | Telemedicine | 1 | 2020 | 666 | 0.100 |
Why?
| | Arthritis, Reactive | 1 | 2012 | 8 | 0.100 |
Why?
| | Patellofemoral Joint | 1 | 2012 | 8 | 0.100 |
Why?
| | Synovial Fluid | 1 | 2012 | 56 | 0.100 |
Why?
| | Eosinophilia | 1 | 2014 | 186 | 0.100 |
Why?
| | Myositis | 1 | 2012 | 43 | 0.100 |
Why?
| | Dyspnea | 1 | 2013 | 211 | 0.090 |
Why?
| | Flatfoot | 1 | 2012 | 38 | 0.090 |
Why?
| | Arthritis, Infectious | 1 | 2012 | 49 | 0.090 |
Why?
| | Sarcoidosis | 1 | 2013 | 133 | 0.090 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2014 | 348 | 0.090 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 924 | 0.080 |
Why?
| | Male | 9 | 2022 | 55112 | 0.070 |
Why?
| | Cost of Illness | 2 | 2020 | 255 | 0.070 |
Why?
| | Registries | 3 | 2020 | 1762 | 0.070 |
Why?
| | Pain | 1 | 2012 | 699 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 1378 | 0.060 |
Why?
| | Accreditation | 1 | 2023 | 76 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2022 | 12504 | 0.050 |
Why?
| | Methotrexate | 1 | 2023 | 227 | 0.050 |
Why?
| | Child, Preschool | 4 | 2020 | 9093 | 0.050 |
Why?
| | Administrative Personnel | 1 | 2021 | 29 | 0.050 |
Why?
| | Infectious Disease Medicine | 1 | 2021 | 10 | 0.050 |
Why?
| | Hematology | 1 | 2021 | 12 | 0.050 |
Why?
| | Patient Handoff | 1 | 2021 | 27 | 0.050 |
Why?
| | Nocardia Infections | 1 | 2021 | 7 | 0.050 |
Why?
| | Pediatric Emergency Medicine | 1 | 2021 | 16 | 0.050 |
Why?
| | Neonatology | 1 | 2021 | 17 | 0.050 |
Why?
| | Gain of Function Mutation | 1 | 2021 | 30 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 4400 | 0.050 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2021 | 33 | 0.050 |
Why?
| | Language | 1 | 2023 | 259 | 0.050 |
Why?
| | Adolescent Medicine | 1 | 2021 | 33 | 0.050 |
Why?
| | Pulmonary Medicine | 1 | 2021 | 69 | 0.040 |
Why?
| | Quality of Life | 2 | 2023 | 2335 | 0.040 |
Why?
| | Multiple Organ Failure | 1 | 2021 | 114 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2021 | 280 | 0.040 |
Why?
| | Endocrinology | 1 | 2021 | 71 | 0.040 |
Why?
| | Family Relations | 1 | 2020 | 84 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 4593 | 0.040 |
Why?
| | Europe | 1 | 2020 | 331 | 0.040 |
Why?
| | Medicine | 1 | 2021 | 102 | 0.040 |
Why?
| | Medical Oncology | 1 | 2021 | 229 | 0.040 |
Why?
| | Resilience, Psychological | 1 | 2020 | 96 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 767 | 0.040 |
Why?
| | Gastroenterology | 1 | 2021 | 159 | 0.040 |
Why?
| | Infant | 1 | 2012 | 7922 | 0.040 |
Why?
| | Focus Groups | 1 | 2020 | 379 | 0.040 |
Why?
| | Phenotype | 2 | 2017 | 2754 | 0.040 |
Why?
| | Qualitative Research | 1 | 2022 | 924 | 0.040 |
Why?
| | North America | 1 | 2018 | 256 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 246 | 0.040 |
Why?
| | Delphi Technique | 1 | 2018 | 157 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 809 | 0.030 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2017 | 28 | 0.030 |
Why?
| | Patient Selection | 1 | 2020 | 625 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 632 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2018 | 251 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 442 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 546 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1356 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 6032 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2019 | 760 | 0.030 |
Why?
| | Panniculitis, Lupus Erythematosus | 1 | 2015 | 1 | 0.030 |
Why?
| | Oral Ulcer | 1 | 2015 | 9 | 0.030 |
Why?
| | Lupus Nephritis | 1 | 2015 | 52 | 0.030 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2014 | 9 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1783 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2020 | 828 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 2875 | 0.030 |
Why?
| | Prevalence | 1 | 2019 | 2244 | 0.030 |
Why?
| | Rheumatic Diseases | 1 | 2014 | 49 | 0.030 |
Why?
| | Societies, Medical | 1 | 2017 | 654 | 0.030 |
Why?
| | Hip Joint | 1 | 2014 | 124 | 0.030 |
Why?
| | Cohort Studies | 1 | 2022 | 4880 | 0.030 |
Why?
| | Physical Exertion | 1 | 2013 | 200 | 0.020 |
Why?
| | Reaction Time | 1 | 2013 | 375 | 0.020 |
Why?
| | Biomedical Research | 1 | 2017 | 581 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3318 | 0.020 |
Why?
| | Thrombosis | 1 | 2014 | 293 | 0.020 |
Why?
| | Skin | 1 | 2015 | 650 | 0.020 |
Why?
| | Heart Diseases | 1 | 2014 | 327 | 0.020 |
Why?
| | Kidney | 1 | 2015 | 1179 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2364 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2012 | 662 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 1822 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 6189 | 0.020 |
Why?
| | Autoantibodies | 1 | 2015 | 1349 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2013 | 2993 | 0.020 |
Why?
| | Young Adult | 1 | 2020 | 10400 | 0.020 |
Why?
| | Risk Factors | 1 | 2018 | 8606 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2015 | 5032 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2013 | 4384 | 0.010 |
Why?
| | Adult | 1 | 2023 | 30245 | 0.010 |
Why?
| | Obesity | 1 | 2013 | 2501 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2012 | 9006 | 0.010 |
Why?
|
|
Curran's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|